Disruption of a six-nucleotide miRNA motif improves PKD1 dosage and ameliorates polycystic kidney disease
Nucleic Acids Research · 2026
DOI: 10.1093/nar/gkaf1538 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2026. Verfasst von Ronak Lakhia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Division of Nephrology, UT Southwestern Medical Center, Dallas, TX 75390, United States. Hauptthemen laut MEDLINE: TRPP Cation Channels, MicroRNAs, Polycystic Kidney, Autosomal Dominant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, PKD-RRC Sprint, National Institute of Health.
Abstract (Originalsprache)
Disrupting microRNA interactions to restore protein expression from haploinsufficient genes offers a promising precision-therapy strategy for monogenic disorders. PKD1 heterozygosity underlies autosomal dominant polycystic kidney disease (ADPKD), a disorder affecting nearly 12 million people worldwide, where reduced PKD1 dosage drives progressive cyst formation and kidney failure. We previously identified a 55-bp cis-repressive element in the PKD1 3′UTR. Here, we define a six-nucleotide miR-17 seed match within this element that is sufficient to reproduce PKD1 repression. In vivo base substitution of this motif stabilizes Pkd1 messenger RNA and increases polycystin-1 (PC1) protein levels, producing a robust reduction in cyst growth and preservation of kidney function in mouse models. To therapeutically recapitulate this effect, we developed a steric-blocking oligonucleotide that occludes the motif, stabilizes PKD1 transcript levels, increases PC1 expression, and mitigates cyst-pathogenic events in both murine and patient-derived ADPKD cells. Together, these findings establish a minimal, targetable cis-regulatory motif and provide proof of concept for oligonucleotide-mediated PKD1 derepression, while offering a potentially generalizable strategy to restore other haploinsufficient genes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Division of Nephrology, UT Southwestern Medical Center, Dallas, TX 75390, United States.
ORCID-Profile: Ronak Lakhia
Förderung
- NIDDK NIH HHS
- PKD-RRC Sprint
- National Institute of Health
Zitieren
APA
Lakhia, R., Song, C., Biggers, L., Zumwalt, M., Alvarez, J., Somasundaram, A., Ramalingam, H., Cobo-Stark, P., & Patel, V. (2026). Disruption of a six-nucleotide miRNA motif improves PKD1 dosage and ameliorates polycystic kidney disease. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf1538
Vancouver
Lakhia R, Song C, Biggers L, Zumwalt M, Alvarez J, Somasundaram A, et al. Disruption of a six-nucleotide miRNA motif improves PKD1 dosage and ameliorates polycystic kidney disease. Nucleic Acids Research. 2026. doi:10.1093/nar/gkaf1538
BibTeX
@article{Lakhia2026,
author = {Lakhia, Ronak and Song, Chunzi and Biggers, Laurence and Zumwalt, Maggie and Alvarez, Jesus and Somasundaram, Arvind and Ramalingam, Harini and Cobo-Stark, Patricia and Patel, Vishal},
title = {Disruption of a six-nucleotide miRNA motif improves PKD1 dosage and ameliorates polycystic kidney disease},
journal = {Nucleic Acids Research},
year = {2026},
doi = {10.1093/nar/gkaf1538}
}
EUVIMED